While the catalytic core of the Pol II transcription machinery is the same for both basal (activator-independent) and activated transcription as observed in vitro and in vivo, respectively, ...

The genome contains tens of thousands of genes. Like a gigantic orchestra, their interaction is the basis for all vital ...

The results suggest that these minimal activation domains might be engineered to create precise activators for transcription factor-mediated gene therapy.

Kaken Pharmaceutical Co. Ltd.’s license agreement with Johnson & Johnson (J&J) for signal transducer and activator of ...

Activator proteins bind to regulatory sites on DNA nearby to promoter regions that act as on/off switches. This binding facilitates RNA polymerase activity and transcription of nearby genes.

Kaken will take the drug through phase I trials, after which J&J takes over. Under the terms, Kaken banks an up-front payment of $30 million and could collect more than $1.2 billion if development and ...